Article révisé par les pairs
Résumé : Objective: To examine the diagnostic accuracy of a previously developed model for prediction of pre-eclampsia (PE) by a combination of maternal factors and biomarkers at 11–13 weeks' gestation. Methods: This was a prospective first-trimester multicenter study of screening for PE in 8775 singleton pregnancies. A previously published algorithm was used for the calculation of patient-specific risk of PE in each individual. The detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 32, < 37 and ≥ 37 weeks were estimated and compared with those for the dataset used for development of the algorithm. Results: In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. With combined screening by maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor, the DR was 100% (95% CI, 80–100%) for PE < 32 weeks, 75% (95% CI, 62–85%) for PE < 37 weeks and 43% (95% CI, 35–50%) for PE ≥ 37 weeks, at a 10% FPR. These DRs were similar to the estimated rates for the dataset used for development of the model: 89% (95% CI, 79–96%) for PE < 32 weeks, 75% (95% CI, 70–80%) for PE < 37 weeks and 47% (95% CI, 44–51%) for PE ≥ 37 weeks. Conclusion: Assessment of a combination of maternal factors and biomarkers at 11–13 weeks provides effective first-trimester screening for preterm PE. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

Documents en relation

DI-fusion

  • ASPRE trial: performance of screening for preterm pre-eclampsia
    par Rolnik, Daniel Lorber Orber D.L. , Singh, Manika , Molina, Francisca Sonia , Persico, Nicola , Jani, Jacques , Plasencia, Walter , Papaioannou, George , Tenenbaum-Gavish, Kinneret , Nicolaides, Kypros , Wright, David , Poon, Liona L.C. , Syngelaki, Argyro , O'Gorman, Neil , de Paco Matallana, Catalina , Akolekar, Ranjit , Cicero, Simona , Janga, Deepa
    Publication 2017-10
  • Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation
    par Tan, M.Y. , Syngelaki, Argyro , Poon, Liona , Rolnik, Daniel Lorber Orber D.L. , O'Gorman, Neil , Delgado, Juan Luis , Akolekar, Ranjit , Konstantinidou, L. , Tsavdaridou, M. , Galeva, S. , Ajdacka, Urszula , Molina, Francisca Sonia , Persico, Nicola , Jani, Jacques , Plasencia, Walter , Greco, Elena , Papaioannou, George , Wright, AlanF , Wright, David , Nicolaides, Kypros K.H.
    Publication 2018-08
  • Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE
    par Tan, M.Y. , Poon, Liona , Rolnik, Daniel Lorber Orber D.L. , Syngelaki, Argyro , de Paco Matallana, Catalina , Akolekar, Ranjit , Cicero, Simona , Janga, Deepa , Singh, Mandeep , Molina, Francisca Sonia , Persico, Nicola , Jani, Jacques , Plasencia, Walter , Greco, Elena , Papaioannou, George , Wright, David , Nicolaides, Kypros K.H.
    Publication 2018-07
  • ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm
    par Poon, Liona L.C. , Rolnik, Daniel Lorber Orber D.L. , Tan, M.Y. , Delgado, Juan Luis , Tsokaki, Theodora , Akolekar, Ranjit , Singh, Mandeep , Andrade, W. , Efeturk, T. , Jani, Jacques , Plasencia, Walter , Papaioannou, George , Blazquez, A.R. , Carbone, Ilma Floriana , Wright, David , Nicolaides, Kypros
    Publication 2018-06
  • Aspirin Versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
    par Rolnik, Daniel Lorber Orber D.L. , Wright, David , Poon, Liona L.C. , O'Gorman, Neil , Syngelaki, Argyro , de Paco Matallana, Catalina , Akolekar, Ranjit , Cicero, Simona , Janga, Deepa , Singh, Mandeep , Molina, Francisca Sonia , Persico, Nicola , Jani, Jacques , Plasencia, Walter , Papaioannou, George , Tenenbaum-Gavish, Kinneret , Meiri, Hamutal , Gizurarson, Sveinbjorn , Maclagan, Kate , Nicolaides, Kypros K.H.
    Publication 2018-01